Found 8 of ic50 for monomerid = 305249 TargetProto-oncogene tyrosine-protein kinase receptor Ret (aa658-end)(Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 7.60nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE™-TK assay tec...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 7.60nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE-TK assay tech...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret (aa658-end)(Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 7.60nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 7.60nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810R](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 19.3nMAssay Description:The potency of a compound inhibiting G810R mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays contained...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 19.3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE™-TK assay tec...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 19.3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret (aa658-end)(Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 19.3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE-TK assay tech...More data for this Ligand-Target Pair
